Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease.
Fiche publication
Date publication
mars 2020
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr REIMUND Jean-Marie
Tous les auteurs :
Bouguen G, Huguet A, Amiot A, Viennot S, Cholet F, Nachury M, Flamant M, Reimund JM, Desfourneaux V, Boureille A, Siproudhis L,
Lien Pubmed
Résumé
Few data are available on the effects of tumor necrosis factor (TNF) antagonist therapy for patients with internal fistulizing Crohn's disease (CD) and there is debate regarding the risk of abscess. We aimed to assess the long-term efficacy and safety of anti-TNF therapy for patients with internal fistulas.
Mots clés
GETAID, Inflammatory Bowel Disease, Infliximab, Prognostic Factor
Référence
Clin Gastroenterol Hepatol. 2020 Mar;18(3):628-636